Rani Therapeutics Holdings, Inc.
HealthcareNASDAQ:RANI · NASDAQ Global Market
-$0.04 today
Vol 0.90M · Avg 1.15M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-89.9%
avg -274.2%
ROIC
-80.6%
avg -89.1%
ROA
-50.6%
avg -51.8%
Analysis
ROA is currently the strongest return metric at -50.6% versus its period average of -51.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Svai S. Sanford | Chief Financial Officer | $791,411.00 | — | 56 | $325,000.00 | 0.50% |
Kate McKinley | Chief Business Officer | $742,372.00 | — | 48 | $805,500.00 | 1.23% |
Talat Imran | Chief Executive Officer & Director | $549,925.00 | — | 44 | $3.80M | 5.82% |
Mir Hashim | Chief Scientific Officer | $416,000.00 | — | 66 | $123,600.00 | 0.19% |
Mir A. Imran | Executive Chairman | $30,000.00 | — | 69 | $3.80M | 5.82% |
Alireza Javadi | Chief Technical Officer | — | — | 42 | $805,500.00 | 1.23% |
Jesper Hoeiland | Head of Strategy | — | — | 66 | — | — |
Arvinder Dhalla | Vice President of Clinical Development | — | — | — | — | — |
Bella Vazquez | Senior Vice President of People & Administrative Services | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$2.26M
Sells
2
$15.71M
Net Sentiment
$13.45M
Net selling
Most Active
IMRAN MIR A
2 transactions
Analysis
Insiders reported 2 buys worth $2.26M and 2 sells worth $15.71M over the last 12 months. That adds up to net selling of $13.45M. IMRAN MIR A was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$283.43M
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
$180.93M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages RANI?
Rani Therapeutics Holdings, Inc. (RANI) lists 9 active executives. The top listed executive is Svai S. Sanford, Chief Financial Officer.
Are RANI insiders buying or selling?
Recent insider activity shows net selling of $5.33M.
Explore More
Continue the stock analysis
Jump to another research area for this company.